Flibanserin vs Insulin Glargine: side-by-side comparison
Flibanserin (Multifunctional serotonin agonist/antagonist (HSDD)) and Insulin Glargine (Long-acting insulin analogue) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Flibanserin | Insulin Glargine |
|---|---|---|
| Therapeutic class | Multifunctional serotonin agonist/antagonist (HSDD) | Long-acting insulin analogue |
| CAS | 167933-07-5 | 160337-95-1 |
| ATC | G02CX02 | A10AE04 |
| Molecular weight | 390.4 g/mol | 6063 Da |
| Brands with this active ingredient | 1 | 1 |
What they share
Flibanserin and Insulin Glargine share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Flibanserin acts by a different mechanism than Insulin Glargine, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Flibanserin: Flibanserin acts as a serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist, with additional effects on dopamine and norepinephrine signalling. Insulin Glargine: Insulin glargine binds the insulin receptor with similar affinity to human insulin, activating intracellular signalling that increases glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production an…
Indications compared
Flibanserin: Flibanserin is approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women — specifically, acquired (not lifelong) and generalised (not situational) HSDD, with personal distress, not better ex… Insulin Glargine: Insulin glargine is approved as basal insulin therapy in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus when oral or non-insulin injectable therapy is insufficien…
Safety profile
Flibanserin: Common adverse effects include dizziness, somnolence, nausea, fatigue and dry mouth. Insulin Glargine: Hypoglycaemia is the most important adverse effect of any insulin and can be severe in case of missed meals, prolonged exercise, alcohol intake or interaction with other glucose-lowering agents.
Frequently asked questions
Is Flibanserin better than Insulin Glargine? ▾
Flibanserin and Insulin Glargine are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Flibanserin and Insulin Glargine be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Flibanserin
Products with Insulin Glargine
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.